# Official Journal C 209/2014

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 209 |
| | |
| English edition | Information and Notices | Volume 574 July 2014 |

ISSN 1977-091X

Official Journal

of the European Union

C 209

English edition

Information and Notices

Volume 574 July 2014

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2014/C 209/01 | Euro exchange rates | 1 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2014/C 209/01

Euro exchange rates

1

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2014/C 209/02 | Prior notification of a concentration (Case M.7293 — Allergopharma/Stallergenes/Laboratorios LETI/JV) — Candidate case for simplified procedure (
  1
  ) | 2 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2014/C 209/02

Prior notification of a concentration (Case M.7293 — Allergopharma/Stallergenes/Laboratorios LETI/JV) — Candidate case for simplified procedure (
  1
  )

1

2

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 4.7.2014 | EN | Official Journal of the European Union | C 209/1 |
| --- | --- | --- | --- |

4.7.2014

EN

Official Journal of the European Union

C 209/1

---

Euro exchange rates (1)

3 July 2014

2014/C 209/01

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3646 |
| JPY | Japanese yen | 139,06 |
| DKK | Danish krone | 7,4569 |
| GBP | Pound sterling | 0,79650 |
| SEK | Swedish krona | 9,3286 |
| CHF | Swiss franc | 1,2147 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 8,4810 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,439 |
| HUF | Hungarian forint | 311,39 |
| LTL | Lithuanian litas | 3,4528 |
| PLN | Polish zloty | 4,1471 |
| RON | Romanian leu | 4,3888 |
| TRY | Turkish lira | 2,9102 |
| AUD | Australian dollar | 1,4552 |
| CAD | Canadian dollar | 1,4530 |
| HKD | Hong Kong dollar | 10,5770 |
| NZD | New Zealand dollar | 1,5563 |
| SGD | Singapore dollar | 1,7008 |
| KRW | South Korean won | 1 376,98 |
| ZAR | South African rand | 14,7099 |
| CNY | Chinese yuan renminbi | 8,4769 |
| HRK | Croatian kuna | 7,5875 |
| IDR | Indonesian rupiah | 16 278,74 |
| MYR | Malaysian ringgit | 4,3596 |
| PHP | Philippine peso | 59,467 |
| RUB | Russian rouble | 46,7050 |
| THB | Thai baht | 44,212 |
| BRL | Brazilian real | 3,0388 |
| MXN | Mexican peso | 17,7357 |
| INR | Indian rupee | 81,3916 |

Currency

Exchange rate

USD

US dollar

1,3646

JPY

Japanese yen

139,06

DKK

Danish krone

7,4569

GBP

Pound sterling

0,79650

SEK

Swedish krona

9,3286

CHF

Swiss franc

1,2147

ISK

Iceland króna

NOK

Norwegian krone

8,4810

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,439

HUF

Hungarian forint

311,39

LTL

Lithuanian litas

3,4528

PLN

Polish zloty

4,1471

RON

Romanian leu

4,3888

TRY

Turkish lira

2,9102

AUD

Australian dollar

1,4552

CAD

Canadian dollar

1,4530

HKD

Hong Kong dollar

10,5770

NZD

New Zealand dollar

1,5563

SGD

Singapore dollar

1,7008

KRW

South Korean won

1 376,98

ZAR

South African rand

14,7099

CNY

Chinese yuan renminbi

8,4769

HRK

Croatian kuna

7,5875

IDR

Indonesian rupiah

16 278,74

MYR

Malaysian ringgit

4,3596

PHP

Philippine peso

59,467

RUB

Russian rouble

46,7050

THB

Thai baht

44,212

BRL

Brazilian real

3,0388

MXN

Mexican peso

17,7357

INR

Indian rupee

81,3916

---

(1)  Source: reference exchange rate published by the ECB.

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

| 4.7.2014 | EN | Official Journal of the European Union | C 209/2 |
| --- | --- | --- | --- |

4.7.2014

EN

Official Journal of the European Union

C 209/2

---

Prior notification of a concentration

(Case M.7293 — Allergopharma/Stallergenes/Laboratorios LETI/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

2014/C 209/02

| 1. | On 26 June 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Allergopharma GmbH & Co. KG (‘Allergopharma’, Germany), a wholly-owned subsidiary of Merck KGaA (‘Merck’, Germany), Stallergenes S.A. (‘Stallergenes’, France), indirectly controlled by Ares Life Science L.P. (‘ARES’, Luxembourg), and Laboratorios LETI, S.L. Unipersonal (‘LETI’, Spain), a wholly-owned subsidiary of LETI Pharma, S.L. (‘LETI Pharma’, Spain) acquire within the meaning of Article 3(1)(b) of the Merger Regulation, joint control over NewCo GmbH (‘NewCo’, Germany), a newly created company, by way of purchase of shares. |
| --- | --- |

1.

On 26 June 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Allergopharma GmbH & Co. KG (‘Allergopharma’, Germany), a wholly-owned subsidiary of Merck KGaA (‘Merck’, Germany), Stallergenes S.A. (‘Stallergenes’, France), indirectly controlled by Ares Life Science L.P. (‘ARES’, Luxembourg), and Laboratorios LETI, S.L. Unipersonal (‘LETI’, Spain), a wholly-owned subsidiary of LETI Pharma, S.L. (‘LETI Pharma’, Spain) acquire within the meaning of Article 3(1)(b) of the Merger Regulation, joint control over NewCo GmbH (‘NewCo’, Germany), a newly created company, by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:
  —   Allergopharma: active in the fields of allergen immunotherapy, allergy diagnostics and allergy prevention and has operations in 25 countries, with a main focus in Germany,
  —   Stallergens: a global healthcare company specialised in the diagnosis and treatment of allergies which is present in 20 countries and distributes its products in 75 countries,
  —   LETI: a biopharmaceutical company active in the fields of the treatment and diagnosis of allergies, pharmaceutical skincare, in-vitro diagnostics and vaccines. It has production sites in Madrid (Spain) and subsidiaries in Portugal and Germany,
  —   NewCO: will develop mobile environmental exposure chambers for carrying out studies into new preparations for the treatment of allergies, will obtain all the validations and permits that are necessary for their operation and will then market the chambers. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   Allergopharma: active in the fields of allergen immunotherapy, allergy diagnostics and allergy prevention and has operations in 25 countries, with a main focus in Germany,

—   Stallergens: a global healthcare company specialised in the diagnosis and treatment of allergies which is present in 20 countries and distributes its products in 75 countries,

—   LETI: a biopharmaceutical company active in the fields of the treatment and diagnosis of allergies, pharmaceutical skincare, in-vitro diagnostics and vaccines. It has production sites in Madrid (Spain) and subsidiaries in Portugal and Germany,

—   NewCO: will develop mobile environmental exposure chambers for carrying out studies into new preparations for the treatment of allergies, will obtain all the validations and permits that are necessary for their operation and will then market the chambers.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7293 — Allergopharma/Stallergenes/Laboratorios LETI/JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7293 — Allergopharma/Stallergenes/Laboratorios LETI/JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.

---